Furthermore, using both serum CCL2 and NMB, it presented a better discrimination in predicting PNI with an AUC of 0.919 (95% CI 0.838-1.000), suggesting that the combined examination of NMB and CCL2 may be a useful approach to diagnose PNI in cervical cancer patients (Fig. 7l). This evidence concerns the gene NMB and cervical carcinoma.